Obesity Clinical Trial
Official title:
Antiplatlet Effects of Standardized Tomato Extract in Hypertensive Subjects at High Estimated Cardiovascular Risk
The reducing the anti-aggregation properties of platelets significantly decreases the risk of myocardial infarction and the total number of cardiovascular events. In patients who have cardiovascular disease, anti-platelet therapy reduces the risk of serious vascular events. Side effects, such as bleeding, are relatively small so the benefits of anti-platelet therapy in secondary prevention exceed the risk of these side effects. According to guidelines for the treatment of arterial hypertension, PTNT 2015, patients with arterial hypertension (HA) that have a 20% or higher risk for cardiovascular events in the next 10 years, should have ASA included in their treatment to reduce this risk. It has been proved that the use of acetylsalicylic acid in secondary prevention reduces the risk of major cardiovascular events, while the benefits of ASA in primary prevention have recently been debated. The benefits of using ASA in primary prevention should always be confronted with the risk of hemorrhagic complications of this therapy According to 2016 European Guidelines on cardiovascular disease (CVD) prevention in clinical practice, anti-platelet therapy is not recommended in individuals who do not suffer from CVD, due to the increased risk of major bleeding. It is important to look for alternative anti-platelet therapy for people with cardiovascular risk factors. Standardized tomato extract (STE) does not cause side effects and may have multiple beneficial effects on total cardiovascular risk, primarily by inhibiting platelet aggregation. Since its discovery in 1999, several studies and human trials with STE have been carried out. During the last 50 years, tomato (Lycopersicon esculentum) has become a highly consumed food. The benefits of inhibiting platelet activity through diet are currently difficult to determine due to the lack of clear and comprehensive scientific data. It is difficult to specify the over activity of the plaques or their proper activity. However, there are data available that indicate the benefits of a diet containing diminishing activity of platelets (Mediterranean diet) and lowering cardiovascular risk.The investigators want to conduct a comparison of the less common STE with clinically recognized ASA. The aim of the study was to compare the anti-platelet effect of STE and ASA in hypertensive patients with high cardiovascular risk.The study highlights that STE may be an alternative, food-based strategy to control the platelets reactivity.
Study design The study involved 82 high-risk hypertensive patients (44 men and 38 women),
aged 28-74years, conducted between July 2015 and February 2017 in the Department of
Hypertension at the University of Medical Sciences in Poznan. Seventeen patients reported
resignation during the study. The permission no. 377/15 to conduct the study was published by
the Ethics Committee at the Poznan University of Medical Sciences. All the patients gave
informed consent for participation in the study. Patients with primary hypertension and high
cardiovascular risk were randomly assigned to one of two groups. Group 1(ASA) included 33
patients who received acetylsalicylic acid at a dose of 75 mg in the morning. Group 2 (STE)
included 32 patients receiving standardized tomato extract (STE) (ZAAX, Sequia, Poland) at a
dose of 213 mg orally in the morning.
The patients had two visits within 4 weeks according to the scheme:
Visit 1: During the first visit, patients were qualified for the study. The patients with
previously diagnosed hypertension were referred from an outpatient clinic, to the hospital
ward. After admission, the patients with high cardiovascular risk were isolated and written
consents were obtained.
On the basis of stage of hypertension, presence of risk factors and subclinical organ damage,
diabetes coexistence, cardiovascular complications and chronic kidney disease the
cardiovascular risk was estimated. Each patient with one or two risk factors and a blood
pressure (BP) > 180/110 mmHg or three or more risk factors, and a BP >160/100 mmHg or with
the presence of organ damage and BP >140/90 mmHg were classified as a high risk Group.There
have been no changes in the concomitant treatment (lipid-lowering, anti-hypertensive and
antidiabetic) during the study.
Numerous laboratory tests and imaging, such as aldosterone and ARO levels, both before and
after tilting, creatinine, urea, GFR, sodium, potassium, pro BNP, TSH, FT3, FT4, and a
24-hour collection for electrolytes were collected. Abdominal ultrasound examinations,
computed tomography of the abdomen, and Doppler ultrasound of the renal arteries were
performed to exclude secondary causes of hypertension. Clinical BP measurements were
performed three times, as well as, ambulatory blood pressure monitoring (ABPM) and
echocardiography was conducted. Whole blood samples were taken and baseline platelet
aggregation was determined using the VerifyNow analyzer from Accumetrics. In Group 1, two
whole blood samples for VerifyNow Aspirin test were assayed. In Group 2, four whole blood
samples for VerifyNow Aspirin and P2Y12 tests were assayed.
Visit 2: After 4 weeks of taking STE or ASA the patients visited the hospital for the second
visit. All examinations from visit 1, including platelet aggregation inhibition assays, were
repeated. Whole blood samples were collected 1-4 h after the ingestion of a morning ASA or
STE dose from a peripheral vein using a 21 gauge or larger needle in a partial fill 3.2%
citrate vacuum collection tube.
Standarized tomato extract characteristics STE is a water-soluble tomato concentrate, free of
lycopene and fats, which contains 37 biologically active compounds of well-known structure.
These bioactive compounds contain nucleosides (adenosine, cytidine, guanosine, inosine, AMP,
GMP), polyphenols including flavonoids (rutin, quercetin, kemferol, luteoline, naryngenin)
and phenolic acids (chlorogenic, coffee, p-coumar, ferulic).
In 2009, the European Food Safety Authority (EFSA) approved the water soluble tomato
concentrate (WSTC) as a food supplement which helps to maintain normal platelet aggregation.
EFSA recommended the use of STE in healthy individuals between 35 and 70. The effective daily
dose was 3 g of bioactive compounds contained in syrup or 65-150 mg in powdered form.
This extract affects the inhibition of ADP-mediated aggregation, thromboxane, collagen, von
Willebrand factor, thrombin and inflammatory mediators. What is more, it blocks the P2Y12
receptor for ADP and limits intracellular granular release of thromboxane, ADP, selectin P
and factor 4 (PF4, platelet factor 4). Additionally, it prevents activation of αIIbβIII
integrin and inhibits (GP) IIb / IIIa receptor activation. By inhibiting the P2Y12 receptor
for ADP, it increases cAMP activity and this results in decreasing intracellular calcium ions
concentration. Inhibition of collagen binding process with GP VI as well as von Willebrand
factor with GP Ib receptor and decrease in Cβ and Cy2 phospholipase activity are also
included in anti-aggregation effects of STE. These phenomena affect the shape of thrombocytha
and are reversible while maintaining a level of platelet activity that allows aggregation in
case of vascular injury. ZAAX can be used by people with hypersensitivity to salicylates and
other non-steroidal anti-inflammatory drugs, with bronchial asthma, with active peptic
ulceration.
Studies have shown that STE inhibits the activation of endothelial inflammatory processes,
which prevents the development of atherosclerosis. STE reduces the production of inflammatory
cytokines (TNF-α, IL-1β and IL-12) and to increases the synthesis of interleukin 10, which
has anti-inflammatory properties.
VerifyNow® Tests Procedure The study protocol included measurements of platelet reactivity
using a VerifyNow Tests Procedure (Accumetrics Inc., USA). This method detects platelet
activity by measurement of platelet aggregation, in a blood sample, exposed to a specific
agonist. This leads to an inhibition of platelet function in response to anti-platelet
therapy. The VerifyNow System is a whole blood device that performs qualitative measurement
of induced platelet aggregation based on the increase in light transmittance. Two types of
VerifyNow test kits were used in the study: VerifyNow Aspirin Test and VerifyNow P2Y12. The
Aspirin test results are reported as Aspirin Reaction Units (ARU), which are calculated as a
function of the rate of aggregation. ARU values less than 550 indicate effective result of
ASA, while values > 550 ARU indicate no effect of the drug. The VerifyNow P2Y12 test measures
platelet function based on the ability of activated platelets to bind fibrinogen and provides
information on the aggravation of platelet aggregation in reactivity units of P2Y12 receptor
(PRU). It is considered that the range of 95 - 208 PRU is responsible for optimal
antiplatelet activity. High PRU values after drug administration, point to the lack of
expected anti-platelet effect.
Blood pressure measurements In all the patients, during each visit, BP measurements were
performed three times at rest, in the supine position, in standard conditions, and using an
upper arm blood pressure monitor (Omron 705IT). Ambulatory, 24-hour blood pressure
measurements (ABPM) were carried out using an A&D, 24-hour ambulatory peripheral blood
pressure monitor. The frequency of measurements was every 15 minutes between 7:00 and 22:00
and every 30 minutes between 22:00 and 7:00.
Statistical analysis Statistical analyses were performed with Statistica, version 12.5.
(StatSoft, USA). Since the tested data did not meet the assumption of Gaussian distribution
(evaluated with Shapiro-Wilk method), the non-parametric methods were applied. The Wilcoxon
signed-rank test was used for evaluation of the differences between the initial values and
the values obtained after the treatment, for factors of; body weight composition, blood
pressure, and platelet aggregation. To evaluate differences and correlations between the two
independent groups the Mann-Whitney U test and Spearman׳s rank correlation coefficient (Rs)
were used, respectively. The data presented on graphs and tables included median and
interquartile ranges. A p<0.05 was considered as significant.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |